Publications by authors named "Simon A Rule"

Claim this Profile
P
Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.
Franck Morschhauser, Martin J S Dyer, Harriet S Walter, Alexey V Danilov, Loic Ysebaert, Simon A Rule

Leukemia· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Alexey V Danilov, Charles Herbaux, Harriet S Walter, Peter Hillmen, Simon A Rule

Clin Cancer Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).
Simon A Rule, Guillaume Cartron, Christopher Fegan, Franck Morschhauser, Lingling Han

Leukemia· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
David L Tucker, Georgina Naylor, Anton Kruger, Malcolm S Hamilton, George Follows, Simon A Rule

Br J Haematol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.
Harriet S Walter, Sandrine Jayne, Simon A Rule, Guillaume Cartron, Franck Morschhauser

Blood· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib for mantle cell lymphoma.
David L Tucker, Simon A Rule

Future Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Harriet S Walter, Simon A Rule, Martin J S Dyer, Lionel Karlin, Ceri Jones

Blood· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.
David L Tucker, Simon A Rule

Ther Clin Risk Manag· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does transcutaneous electrical nerve stimulation (TENS) alleviate the pain experienced during bone marrow sampling in addition to standard techniques? A randomised, double-blinded, controlled trial.
David L Tucker, Mark Rockett, Mehedi Hasan, Sarah Poplar, Simon A Rule

J Clin Pathol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.
Heather E Eve, Sean Carey, Sarah J Richardson, Carla C Heise, Vidya Mamidipudi, Simon A J Rule

Br J Haematol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indolent mantle-cell lymphoma: immunoglobulin variable region heavy chain sequence analysis reveals evidence of disease 10 years prior to symptomatic clinical presentation.
Simon A J Rule, Sarah Poplar, Paul A S Evans, Sheila J M O'Connor, Roger G Owen

J Clin Oncol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide-induced tumour flare reaction in mantle cell lymphoma.
Heather E Eve, Simon A J Rule

Br J Haematol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autoimmune haemolytic anaemia associated with mantle cell lymphoma.
Heather E Eve, Simon A J Rule

Int J Hematol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma.
Heather E Eve, Michelle V Furtado, Michael D Hamon, Simon A J Rule

J Clin Oncol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: results of a randomized phase II trial.
Heather E Eve, Jo Gambell, Paul Smith, Wendi Qian, Simon A J Rule

Leuk Lymphoma· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab.
Heather E Eve, John F Seymour, Simon A J Rule

Leuk Lymphoma· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study.
Heather E Eve, David Linch, Wendi Qian, Moira Ross, John F Seymour, Simon A J Rule

Leuk Lymphoma· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac involvement with mycosis fungoides: could this explain alemtuzumab toxicity?
Kerry Ann Sleigh, Mark E F Smith, Simon A J Rule

Leuk Lymphoma· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiological doses of cannabinoids do not adversely affect MCL viability.
Sarah J Richardson, Mathieu Widmer, John Zajicek, Simon A Rule

Leuk Lymphoma· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.
D Wayne Thomas, Roger G Owen, Stephen A N Johnson, Peter Hillmen, John F Seymour, Simon A J Rule

Leuk Lymphoma· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of "touchdown" polymerase chain reaction increases the sensitivity and specificity of t(11;14)(q13;q32) detection in patients with mantle cell lymphoma.
Andrew W Duckworth, Simon A J Rule

Br J Haematol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing cutaneous reactions to imatinib therapy.
Simon A J Rule, Stephen G O'Brien, Lucy C Crossman

Blood· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Position paper on imatinib mesylate in chronic myeloid leukaemia.
Stephen G O'Brien, Simon A J Rule

Br J Haematol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis